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Abstract 
 
Juvenile-onset systemic lupus erythematosus (JSLE) is a rare, severe multisystem 
autoimmune disease affecting the kidney (Lupus Nephritis, LN) in up to 80% of children. LN 
is more severe in children than adults, with potential for irreversible kidney damage requiring 
dialysis or transplant. Renal biopsy is currently the gold standard for diagnosing and 
monitoring LN, however, it is invasive and associated with complications. Urine biomarkers 
have been shown to be better than serum biomarkers in differentiating renal disease from 
other organ manifestations. Over the past decade, there have been an increasing number of 
studies investigating specific candidate biomarkers implicated in the pathogenesis of LN or 
screening for urinary biomarkers using hypothesis free methods. In this review, developments 
in urine biomarkers for LN will be reviewed, highlighting those that are of relevance to 
children and have gone through validation in independent international patient cohorts, 
bringing them close to clinical translation.  
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Abbreviations 
AGP = α-1 acid glycoprotein, 
ANA = anti-nuclear antigen 
AUC = area under the curve 
β2MG = Beta-2-microglobulin 
BILAG = British Isles Lupus Assessment Group score 
C3 = complement factor 3 
C4 = complement factor 4 
CKD = chronic kidney disease patients 
CrCl = creatinine clearance 
CXCL16 = Chemokine (C-X-C motif) ligand 16  
CXCR3 = Chemokine receptor 3 
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Fn14 = fibroblast growth factor-inducible 14  
FLCs = free light chains  
FSGS = focal segmental glomerulosclerosis  
GFR = glomerular filtration rate 
HC’s = healthy controls 
IFN-! = interferon gamma 
IL = interleukin  
IP-10 = Interferon-!-inducible protein 10 
ISN/RPS = International Society of Nephrology / Renal Pathology Society  
JIA = juvenile idiopathic arthritis  
JSLE = Juvenile-onset systemic lupus erythematosus  
Κ-FLC= κ free light chain 
KIM-1 = kidney injury molecule 1 
L-FLC= lamda free light chains 
LC-MS = Liquid chromatography coupled to mass spectrometry  
LC/MS/MS = liquid chromatography-nanospray tandem mass spectrometry  
LN = lupus nephritis 
MALDI-TOF MS = Matrix-assisted laser desorption/ionization time-of- flight mass 
spectrometry  
MCP-1 = Monocyte chemoattractant protein-1 
NIH = National Institute for Health 
NGAL = Neutrophil gelatinase associated lipoclain 
PGDS = Prostaglandin-H2-D isomerase, alternative name LPGDS 
RA = rheumatoid arthritis  
RANTES = regulated on activation, normal T cell expressed and secreted 
RBP-4 = retinol binding protein 4 !
ROC = receiver operating curve 
SELDI-TOF = Surface-enhanced laser desorption/ionization time of flight technology 
SLE = systemic lupus erythematosus 
SLEDAI = SLE disease activity index  
SLICC!=!Systemic Lupus Collaborating Clinics  
TF = transferrin 
TWEAK = Tumor necrosis factor (TNF)-like weak inducer of apoptosis  
VCAM-1 = Vascular cell adhesion molecule-1   
WHO = world health organization 
ZA2G = Zn-alpha2-glycoprotein !
 
 
1! Introduction 
Juvenile-onset systemic lupus erythematosus (JSLE), also know as childhood-onset SLE, is a 
rare, severe multisystem autoimmune disease. Twenty percent of cases of SLE are diagnosed 
during childhood, with up to 80% of JSLE patients developing lupus nephritis (LN) [1], 
compared with 40-50% or adults [2,3]. LN may be part of the patients’ initial presentation or 
occur later in the disease. Renal biopsy is currently the gold standard for diagnosing LN, 
characterizing disease activity and providing insight into the degree of scarring and 
irreversible damage to the kidney [4,5]. However, the invasive nature of the procedure, risk 
of complications such as bleeding or infection, and need for anaesthetic in children, lead to a 
tendency for the procedure to be avoided until deemed absolutely necessary. Clinicians 
therefore rely heavily upon less invasive markers including proteinuria, serum creatinine, 
glomerular filtration rate (GFR), urine microscopy, immunological, hematological and 
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inflammatory biomarkers when monitoring patients and making a decision whether to 
undertake a renal biopsy. At present, there is no consensus as to the optimal timing of an 
initial renal biopsy for diagnosing LN in children, with clinical concern that irreversible renal 
damage may occur prior to the onset of clinically overt disease [6].  
 
Following a histological diagnosis of LN, on-going monitoring tends to again rely on the 
above blood and urine tests, however, these investigations have many limitations which 
require recognition. Following a LN flare, proteinuria can take a significant period of time to 
normalize, making it difficult to differentiate proteinuria due to irreversible damage of the 
glomerular capillaries or on-going LN activity [7]. Changes in serum creatinine tend to lag 
behind changes in glomerular filtration rate and are also influenced by the child’s age, gender 
and height [8]. Of concern, there have been reports of ‘clinically silent LN' in patients with 
biopsy defined LN but no proteinuria, normal urinalysis and normal renal function [9]. 
Repeat biopsy of patients who have shown a complete clinical renal response has found 
approximately one third to have on-going evidence of LN activity, and approximately 60% to 
display chronicity index features [10]. Normal complement and anti-dsDNA antibodies may 
provide reassurance that active LN is improbable, however, studies looking at the accuracy of 
these tests for differentiating between patients with active and in-active LN have shown 
conflicting results [11-13].  
 
2! Pursuit of novel biomarkers for LN  
Clearly, the performance of conventional blood and urine tests for LN diagnosis and 
monitoring is inadequate. LN therapy could be more effective, treatment toxicity limited, and 
renal outcomes improved if LN onset, severity, and treatment responsiveness could be 
predicted. Early treatment and rapid induction of LN remission has been shown to improve 
renal survival, highlighting the need for improved LN detection and monitoring [14,15]. To 
this end, novel, non-invasive biomarkers of disease activity and prognosis are increasingly 
being investigated. To translate an experimental biomarker into clinical practice, Mischak et 
al [16] describe a six step process which we should be mindful of when evaluating novel 
biomarkers studies. This process includes: (1) initial biomarker identification / verification, 
(2) evaluation of the results by independent experts, (3) evaluation in a suitable bio bank of 
existing samples or newly collected samples, (4) evaluation in a clinical trial, (5) 
implementation in clinical practice, and (6) proving the cost-effectiveness of the validated 
biomarker. The majority of LN urine biomarker studies to date have focused upon step one to 
three of this process.   
 
3! The importance of assessing all novel biomarkers in children as well as adults 
 
Juvenile and adult onset SLE differ in many ways. Juvenile onset disease is associated with 
more severe disease phenotype, including more renal involvement [1,17-21] and damage than 
in adult counterparts [17]. Compared with adult onset (18-50 years) and late onset SLE (>50 
years old), juvenile onset patient have been shown to be at highest risk of renal failure and 
mortality [22]. Approximately 10% of children with proliferative nephritis progress to end-
stage renal disease within 5 years [23], with irreversible renal damage remaining as one of 
the most common long-term consequences seen in JSLE [24]. It is anticipated that the 
differences in LN severity between juvenile and adult onset SLE populations may bear 
influence on the level of biomarkers reflecting the degree of renal injury within such 
populations. Urine biomarkers which are derived from plasma proteins may also show 
differences in their levels due to age dependent differences in plasma levels of the given 
protein. Childhood specific biomarker discovery and validation studies are therefore 
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important to explore these issues and in view of the fact that children tend to have fewer co-
morbidities (e.g. diabetes, cardiovascular disease or hypertension) which can confound the 
results of urine biomarker studies. Consequently, it may be that a biomarker is useful in a 
paediatric but not an adult SLE population, or vice versa. This may account for some of the 
differences in proteins identified from paediatric and adult SLE urine proteomic studies [25-
27]. In light of such observations it has been proposed that all biomarker studies should be 
concurrently carried out on children as well as adults with SLE [28].  
 
4! Why urine? 
In LN, urine is increasingly becoming recognized as the most useful and desirable medium 
for biomarker discovery due to the non-invasive nature of sample collection and its ability to 
reflect kidney damage, given its close proximity to native renal cells. Plasma and serum are 
more complex sample types which are in contact with multiple organs and therefore less 
likely to yield organ specific biomarkers. The smaller number of core proteins in urine than 
plasma / serum (approximately 2000 vs. 10,000) also make urine a better medium for 
harvesting biomarkers [29,30].  
 
Under physiological conditions, a relatively small amount of protein is excreted into the urine 
due to the highly efficient glomerular filtration barrier which consists of fenestrated 
endothelium, the collagenous glomerular basement membrane, and podocytes, with their 
interdigitating foot processes and slit diaphragms. These three layers restrict movement of 
proteins into the urine on the basis of their molecular weight, size and electrical charge. In 
glomerular diseases such as LN, this barrier is disrupted leading to leakage of plasma / serum 
proteins alongside secretion of specific proteins reflective of the inflammatory state and 
kidney damage [31]. The pathogenesis of LN is known to involve multiple inflammatory 
cells, cytokines, chemokines, adhesion molecules and their receptors. Efforts to identify 
urinary biomarkers to date have related to specific candidate biomarkers implicated in the 
pathogenesis of LN or hypothesis free biomarker screens (e.g. using proteomic techniques). 
In the next section, developments in biomarkers for LN will be reviewed, highlighting those 
that have gone through validation in independent patient cohorts and are of particular 
relevance to children. 
 
5! Urine biomarkers relating to the pathophysiology of LN 
 
5.1! Inflammatory cells as urine biomarkers  
The immune cells known to infiltrate the kidney in LN are known to comprise of T cells, 
macrophages, B cells and plasma cells [32-34]. Urinary cells have been investigated as non-
invasive biomarkers of the inflammatory renal environment, with their relationship to LN 
outcome, therapeutic response or future flares currently under investigation. The specific 
origin of urinary immune cells is unknown but is speculated to relate to peri-glomerular, peri-
tubular or interstitial infiltrates. In a recent study of 19 SLE patients with active LN and 55 
SLE patients without LN using flow cytometry based cell quantification; urinary T cell 
subsets, B cells and macrophage numbers were significantly higher in active LN patients. 
Urinary T cell sub-sets showed excellent distinction between patients with active LN and 
non-LN SLE patients (CD8+ T cells, area under the curve (AUC) of 1.000 and CD4+ T cells 
AUC of 0.9969). CD14+ macrophages performed slightly less well (AUC = 0.9066), and 
CD19+ B cells were only moderately elevated, failing to reach these high standards of 
differentiation between patient groups (AUC = 0.7823) [35]. The same group have previously 
shown that high urinary CD4+ T cells numbers were observed in patients with proliferative 
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LN, and that over time, normalization of urinary CD4 T cell counts was associated with 
lower disease activity and better renal function. Persistence or an increase in urinary T cell 
numbers associated with higher total SLE disease activity index (SLEDAI) scores, and poorer 
renal outcomes in terms of serum creatinine and proteinuria [36]. These results have been 
confirmed by a further group who found urinary CD4+ and CD8+ T-cell counts to 
discriminate between active and inactive LN (AUC 0.92 and 0.93, respectively) [37], and to 
decrease significantly in response to treatment [35].  
 
Long-lived plasma cells (CD138+) are capable of continually secreting autoantibodies. These 
cells live in chronically inflamed tissues like the kidneys in addition to the bone 
marrow/spleen. Urinary free light chains (FLCs) are synthesised by such cells with the total 
urinary FLC levels correlating with the number of CD138+ long-lived plasma cells within the 
kidney and International Society of Nephrology / Renal Pathology Society (ISN/RPS) class 
III/IV LN [38]. Monitoring of urinary immune cells as biomarkers is limited by the relatively 
large volume of urine required to get enough cells for analysis (approximately 100mls as 
opposed to 20-200!l in many immune-assays). The urine also needs to be fresh and analysed 
within six hours of voiding [35]. In the future, measurement of markers associated with these 
cells may provide a simpler proxy for inflammatory cell numbers, and be more suited for 
paediatric studies. 
 
5.2! Cytokines, chemokines and their receptors as urine biomarkers  
Cytokines, chemokines and their receptors play an important role in the pathogenesis of LN. 
This has led to a variety of studies testing whether they may be used as potential urinary 
biomarkers for LN. Multiplex bead assays have made it possible to simultaneously screen for 
multiple cytokines in a single sample, saving precious patient samples and time.  
 
5.2.1! Monocyte chemoattractant protein-1  
Monocyte chemoattractant protein-1 (MCP-1) is one of the most extensively investigated 
urine biomarkers in LN. It is a leucocyte chemotactic factor, which acts to recruit 
inflammatory cells to infiltrate the kidney in LN, leading to inflammation and tissue injury 
[39]. Increased expression of MCP-1 has been demonstrated by immunohistochemistry and 
in situ hybridization in endothelial cells, renal epithelial cells and infiltrating mononuclear 
cells present in the tubulointerstitial region of the kidney in LN [40].  There is also a 
correlation between glomerular expression of MCP-1 and more severe histological classes of 
LN (class III and IV LN), correlating with poor renal prognosis [41]. A large number of 
paediatric and adult cross-sectional studies have consistently demonstrated that urinary levels 
of MCP-1 are elevated in patients with active LN, as compared to controls (those with 
inactive LN and / or healthy controls) [42-49]. Although MCP-1 is associated with renal 
involvement in SLE, it is also elevated in other types of glomerulonephritis [50]. 
 
In a JSLE study, Watson et al [51], examined urinary MCP-1 levels in 64 JSLE patients 
longitudinally, demonstrating MCP-1 to be an independent predictor for active renal disease 
at the time of the current review, and over time, low urinary MCP-1 levels were an excellent 
predictor of future renal disease improvement (AUC: 0.81; p=0.013). In an adult SLE 
longitudinal study, Rovin et al [45] demonstrated that urinary MCP-1 levels were 
significantly higher during renal as opposed to non-renal flares, increasing 2-4 months before 
a LN flare. Patients who responded to treatment showed a decrease in urinary MCP-1 levels 
over several months, whereas non-responders displayed persistently elevated MCP-1 levels. 
MCP-1 levels were also demonstrated to be higher in patients with proliferative LN (WHO 
class III/IV) as opposed to membranous (class V) nephritis. A further longitudinal study of 40 
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adult SLE patients supports these results, with urinary MCP-1 levels falling in responders, 
remaining elevated in non-responders and correlating with histological severity [52]. Of note, 
an adult SLE study including 136 patients found urinary MCP-1 levels to be no better than 
anti-dsDNA antibody or C3 at differentiating renal vs. non-renal SLE flares [53]. A further 
study by Tian et al [54] showed that MCP-1 was unable to predict the occurrence of a LN 
flare in advance.  
 
MCP-1 antagonists have been shown to ameliorate lupus nephritis in MRL-(Fas)lpr 
autoimmune prone mice [55], and to permit a 75% reduction in the dose of 
cyclophosphamide required to control diffuse proliferative LN in such mice [56]. MCP-1 
antagonists have also been investigated in early phase type 2 diabetes [57] and post-traumatic 
neuralgia [58] trials but are not currently being investigated in LN. See Table 1 for a 
summary of the evidence relating to MCP-1 in children. 
 
5.2.2! Neutrophil gelatinase associated lipocalin  
Urinary neutrophil gelatinase associated lipoclain (NGAL) has also been widely investigated 
in LN. It is a member of the lipocalin family of carrier proteins that is expressed by many cell 
types including neutrophils and renal tubular epithelial cells. It is responsible for cellular iron 
transport, apoptosis, bacteriostasis and tissue differentiation, and is implicated in the growth 
and differentiation of epithelial cells [59]. NGAL is constitutively expressed at low levels in 
the kidneys [60], and is up-regulated in response to acute renal injury in responses to 
inflammation, ischemia and infection [61-65]. It has been shown to be a useful non-invasive 
marker of acute kidney injury following cardiopulmonary bypass surgery in children [66], 
and is predictive of the need for dialysis in diarrhea-associated hemolytic uremic syndrome 
and renal graft rejection [61,67]. 
 
The first paediatric urinary NGAL study was carried out by Brunner at al [68] in a small 
cohort of 35 JSLE patients. They reported higher levels of urinary NGAL in JSLE compared 
to juvenile idiopathic arthritis (JIA) patients. NGAL levels were strongly to moderately 
correlated with renal SLEDAI defined disease activity and Systemic Lupus Collaborating 
Clinics (SLICC) defined damage, but not with extra-renal disease activity. Subgroup analysis 
showed NGAL levels to be highly sensitive and specific for identifying JSLE patients with 
biopsy-proven nephritis. In a further study, they found the combination of NGAL together 
with MCP-1 and creatinine clearance to be good for identifying LN chronicity (AUC 0.83) 
[69]. In an independent Egyptian paediatric cohort including 35 JSLE patients, urinary 
NGAL was shown to correlate with the renal SLEDAI score and be predictive of class III and 
IV LN with 91% sensitivity and 70% specificity [70]. Pitashny et al [71] demonstrated 
urinary NGAL levels to be significantly higher in LN than non-LN patients in a cohort of 70 
adult SLE patients. Urinary NGAL levels correlated significantly with renal but not with 
extra-renal SLEDAI scores. 24 hour urinary NGAL excretion has been shown to be a 
potential biomarker of renal damage in adult SLE patients, correlating with serum creatinine 
and creatinine clearance but not the SLEDAI score [72]. 
 
NGAL has also been investigated in two paediatric longitudinal studies, where it has been 
demonstrated to be predictive of LN flare [51,73]. Suzuki et al [73] studied 85 JSLE, 30 JIA 
patients, and 50 HC’s. They found plasma and urinary NGAL levels to be increased in JSLE 
patients compared to controls, with urinary NGAL being significantly associated with 
worsening of renal disease. A subsequent paper reporting ongoing longitudinal follow-up (≥ 
3 follow-up visits) within this cohort, described urinary NGAL levels as increasing by up to 
104%, up to 3 months before worsening of LN [74]. Watson et al [51], demonstrated urinary 
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NGAL to be a good predictor of worsening renal disease activity (AUC 0.76; p=0.04) over 
time in a study involving 64 JSLE patients. Similarly, in an adult SLE study which included 
the exploratory Einstein Lupus Cohort and a validation cohort from University College 
London, urinary NGAL levels were found to rise 3-6 months before renal flare and to 
perform better than anti-dsDNA antibody for prediction of renal flare [75]. However, in 
contrast to the above, a longitudinal study involving 107 adult SLE patients was unable to 
identify an association between urinary NGAL and any measure of LN disease activity [76]. 
These conflicting results may be explained by differences in the timing of the sample and the 
outcome measures used. See Table 1 for a summary of the evidence relating to NGAL in 
children. 
 
5.2.3! Vascular cell adhesion molecule-1 
Vascular cell adhesion molecule-1 (VCAM-1) has not been investigated in paediatric urinary 
biomarker studies to date, and warrants further investigation in this population. It is an 
adhesion molecule and member of the immunoglobulin superfamily, which interacts with 
integrins, supporting tethering and adhesion of leukocytes to endothelial cells and migration 
into organs such as the kidney. Wu et al [77], demonstrated that urinary levels of VCAM-1 
correlate well with urine protein levels and disease activity scores in three murine lupus 
nephritis models. They extended their work to compare urine samples from 38 SLE patients, 
15 normal controls and six rheumatoid arthritis (RA) control patients. SLE patients displayed 
significantly higher urinary VCAM-1 levels than controls, with LN patients exhibiting the 
highest VCAM-1 levels. Urinary VCAM-1 levels also correlated with urine protein to 
creatinine ratios and renal SLEDAI score.  
Several other small cross-sectional studies have since looked at urinary VCAM-1 in human 
LN. Molad et al [78], looked at 24 SLE patients compared to HC’s, showing urinary VCAM-
1 to be significantly increased in the SLE patients, and to correlate with SLEDAI, low C3, 
creatinine clearance and albuminuria. Abd-Elkareem et al [79], studied 50 SLE patients (30 
active LN, 20 no LN) and found elevated urinary VCAM-1 in class III, IV and V LN but not 
in class I/II, or non LN SLE patients. Howe et al [80], also showed urinary VCAM-1 to be 
significantly increased in active versus inactive LN in 121 SLE patients (33 with active LN). 
More recently, Singh et al [43], found VCAM-1 to discriminate between active and inactive 
LN (AUC 0.92), correlating positively with the renal pathology activity index and the 
presence of class IV LN. In a longitudinal study of 107 SLE patients followed for up to eight 
clinic visits, urinary VCAM-1 levels were shown to correlate with renal SLICC score, urine 
protein/creatinine ratio and physicians global assessment, but not renal histology [76].  
5.2.4! Tumor necrosis factor-like weak inducer of apoptosis  
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a soluble cytokine that is 
mainly produced by leukocytes, but also by resident renal cells, leading to elevated TWEAK 
expression within the kidney and urine of adults with lupus nephritis [81,82]. Expression of 
Fibroblast growth factor-inducible 14 (Fn14), the TWEAK signaling receptor, is rapidly 
unregulated in context of tissue injury, autoimmune / inflammatory diseases, and has been 
shown to be present on podocytes, endothelial, mesangial and tubular cells [82]. TWEAK / 
Fn14 signaling mediates a variety of physiological processes, including cellular proliferation, 
survival, differentiation, migration, angiogenesis, induction of cell death, up-regulation of 
pro-inflammatory mediators and chemoattractants. The TWEAK ⁄ Fn14 pathway is felt to 
promote local tissue regeneration and repair after acute injury but conversely, is also involved 
in tissue damage and pathological tissue remodeling in diseased end organs in the context of 
excessive or persistent Fn14 up-regulation [83,84]. Of note, blocking TWEAK/Fn14 
interaction in murine inflammatory kidney disease leads to improvement in disease [84] and 
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Fn14 deficiency in a lupus prone mouse strain has been shown to ameliorate the diseases 
clinical phenotype [85].  
 
Substantial evidence has accumulated for the role of urinary TWEAK as a biomarker for LN 
in adult SLE patients. In a cross-sectional study of 83 adult SLE patients, Schwartz et al [86], 
found urinary TWEAK levels to be significantly higher in patients with active LN vs. non-
LN SLE patients, with TWEAK levels being higher during renal vs. non-renal flares and  
correlating with the renal SLEDAI score. Longitudinal follow-up of a subgroup of these 
patients, within a larger multicenter cohort, found urinary TWEAK levels were significantly 
higher during a renal flare than 4-6 months prior to/following a flare. A linear mixed-effects 
model showed a significant association between urinary TWEAK levels and disease activity 
over time. Urinary TWEAK levels were again higher in LN patients that non-LN SLE 
patients and also controls (diabetes related kidney disease, hypertension, RA or 
osteoarthritis). There was no significant association between TWEAK and LN histological 
classes [81]. Two subsequent cross-sectional studies looking at urinary TWEAK have 
demonstrated significantly higher TWEAK levels in adult SLE patients with active LN 
compared to those with no nephritis [44,87]. Further investigation in children and young 
people with SLE is warranted. 
5.2.5! IL-6 
IL-6 has not been investigated in a paediatric study to date. Two small adult SLE studies have 
suggested a role for IL-6 as a urinary biomarker for LN. The first included 29 patients with 
active LN and showed IL-6 levels to be higher in those with WHO class IV LN on biopsy 
than other classes [88]. A second study of 27 SLE patient and 17 HC’s also found urinary IL-
6 to be higher in active LN, compared to inactive LN and HC’s [89]. However, in a larger 
study comparing urinary IL-6 in 143 patients with SLE, 128 with a positive anti-nuclear 
antigen (ANA, but <3 ACR criteria) and 73 HC’s, IL-6 was high in the first two groups of 
patients, with no difference seen between SLE patients with / without LN [90].  
 
5.2.6! Other chemokines and their receptors  
Interferon-!-inducible protein 10 (IP-10) is a chemokine produced by monocytes, endothelial 
cells and fibroblasts in response to IFN-!. IP-10 promotes migration into the kidney of T-
cells expressing the IP-10 receptor (Chemokine receptor 3, CXCR3), and an increase in 
CXCR3+CD4+ T cells has been demonstrated in LN kidney tissue and urine, correlating with 
disease activity [91]. IP-10 has also been shown to promote mesangial cell proliferation in 
adults with proliferative glomerulonephritis [92], with tubulo-interstitial IP-10 expression 
decreasing in serial biopsies where a LN patient changes from having proliferative / mixed 
nephritis to membranous nephropathy [93]. Avihingsanon et al [94], evaluated urinary 
mRNA levels of IP-10 and CXCR3, demonstrating that urinary mRNA levels of IP-10 and 
CXCR3 were significantly higher in class IV LN compared with classes II, III and V. A 
significant reduction in IP-10 and CXCR3 mRNA level was seen in patients who responded 
to treatment, whereas levels remained elevated in treatment resistant patients. Abujam et al 
[53], assessed urinary IP-10 and MCP-1 levels in the urinary supernatant of 138 adult SLE 
patients, demonstrating a significant difference in the levels of both biomarkers between 
active LN, active non-renal SLE patients and HC’s.  In ROC analysis, MCP-1 out performed 
IP-10 in its ability to identify active LN (AUC 0.78 vs. 0.68 respectively). Within a paediatric 
study, no difference in urinary supernatant IP-10 levels could be detected between  active 
LN, JSLE non-LN patients or HC’s [42], emphasizing the need to examine urine biomarkers 
in both adult and paediatric studies as differences may exist.  
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Chemokine (C-X-C motif) ligand 16 (CXCL16), is a surface bound and soluble chemokine 
produced by T-cells / dendritic cells under the control of IFN-!/TNF-". Urinary CXCL16 has 
been shown to discriminate adult patients with active LN from other SLE patients with an 
excellent AUC of 0.934 [77]. Given the potential role for chemokines and their receptors in 
the pathogenesis on LN, and as biomarkers for LN, further investigation of is required, 
especially within JSLE populations. RANTES (regulated on activation, normal T cell 
expressed and secreted) is a chemokine which is involved in T cell recruitment to inflamed 
sites. In adult patients with diffuse proliferative LN, urinary RANTES has been shown to be 
significantly higher during episodes of flare [54]. No evidence relating to urinary CXCR3, 
CXCL16 or RANTES is available in JSLE. 
 Patients Study design Outcome Ref 
MCP-1 52 in-active LN, 8 
active LN, 20 
HC’s 
Cross-sectional 
 
Renal BILAG 
defined LN 
Significantly higher urinary MCP-1 
concentrations in active LN than patients 
with in-active renal disease or HC’s.  
[42] 
12 in-active LN, 
13 active LN 
Cross-sectional 
 
Biopsy defined 
LN 
Significantly higher urinary MCP-1 
concentrations in active LN than patients 
with in-active renal disease or HC’s.  
[46] 
 
15 active LN, 15 
in-active LN, 15 
never had LN, 15 
HC’s 
Cross-sectional 
 
Biopsy defined 
LN 
Significantly higher urinary MCP-1 
concentrations in active LN than patients 
with in-active renal disease, those who 
have never had LN or HC’s.  
[49] 
 
26 JSLE patients 
aged # 18 years, 
50 SLE patient 
>18 years old. All 
active LN patients 
within 2 months 
of renal biopsy. 
Cross-sectional 
biomarker panel 
 
Biopsy defined 
LN 
•! MCP-1+AGP+CP+ 
protein:creatinine ratio = good for 
detecting LN histological activity 
(AUC 0.85).  
•! MCP1+ AGP+TF+CrCl+C4 = fair 
for membranous LN detection (AUC 
0.75). 
•! MCP-1 +NGAL + Creatinine = good 
test for LN chronicity (AUC 0.83). 
[69]  
47 JSLE patients 
at the time of renal 
biopsy. 
Cross-sectional 
biomarker panel 
 
Biopsy defined 
LN 
National Institute for Health Activity 
Index status predicted by MCP-1, NGAL, 
ceruloplasmin, adiponectin and KIM-1, 
Hemopexin in combination, with >92% 
accuracy. 
[95] 
 
NGAL 12 active LN, 23 
no LN, 8 JIA 
controls 
Cross-sectional 
biomarker panel 
 
SLEDAI-2K 
defined LN (score 
>0 on the renal 
domain) 
Significantly higher urinary NGAL 
concentrations in active LN, than in-
active/no renal disease or JIA controls. 
NGAL levels not correlated with extra-
renal disease or damage. NGAL levels 
>0.6ng/mg creatinine were 90% sensitive 
and 100% specific for identifying JSLE 
patients with biopsy proven LN. 
[68] 
 
26 active LN, 59 
inactive LN, 30 
JIA, 50 HC’s 
 
 
Cross-sectional 
and longitudinal 
(52/85 JSLE 
patients with ≥ 1 
follow-up visit) 
Significantly higher urinary NGAL levels 
in JSLE patients vs. controls. Moderate 
correlation of urinary NGAL with 
SLEDAI-2K defined renal diseases 
[73] 
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SLEDAI-2K 
defined LN (score 
>0 on the renal 
domain) 
activity (r=0.4, p<0.008). Urinary NGAL 
not extra-renal SLEDAI scores.  
 
Longitudinally, urinary NGAL levels 
increased significantly with worsening of 
renal activity. 
22 active LN, 11 
inactive LN 
Cross-sectional  
 
Biopsy defined 
LN 
Significantly higher urinary NGAL 
concentrations in active LN than in-
active LN and HC’s. Urinary NGAL 
predictive of class III and IV LN with 
91% sensitivity and 70% specificity. 
[70] 
26 JSLE patients 
aged # 18 years, 
50 SLE patient 
>18 years old. All 
active LN patients 
within 2 months 
of renal biopsy. 
Cross-sectional 
biomarker panel 
 
Biopsy defined 
LN 
NGAL + MCP-1 + Creatinine = good test 
for LN chronicity (AUC 0.83). 
[69] 
 
47 JSLE patients 
at the time of renal 
biopsy. 
Cross-sectional 
biomarker panel 
 
Biopsy defined 
LN 
National Institute for Health Activity 
Index status predicted by MCP-1, NGAL, 
ceruloplasmin, adiponectin and KIM-1, 
Hemopexin in combination, with >92% 
accuracy. 
[95] 
 
111 JSLE patients 
with 365 follow-
up episodes.  
Longitudinal, at 
least 3 study 
visits. 
 
BILAG, and 
SLEDAI-2K 
defined LN 
Urinary NGAL levels increased by an 
average of 70-104%, up to 3 months 
before worsening of LN. ROC analysis 
for ability of urinary NGAL to predict 
worsening LN gave an AUC of 0.78 
when using SLEDAI-2K renal score as 
the external standard, or 0.80 when using 
the renal BILAG score.  
 
[74] 
 
Table 1: Summary of evidence for cytokines, chemokines and their receptors as urine 
biomarkers in children. MCP-1 = monocyte chemoattractant protein-1, LN = lupus 
nephritis, HC’s = healthy controls. JIA = juvenile idiopathic arthritis. BILAG = British Isles 
Lupus Assessment Group score, AGP = α-1 acid glycoprotein, TF = transferrin, CrCl = 
creatinine clearance, C4 = complement factor 4, AUC = area under the curve, NGAL = 
neutrophil gelatinase associated lipocalin, KIM-1 = kidney injury molecule 1, SLEDAI-2k = 
SLE disease activity index. 
 
6! Proteomic based urine biomarker analysis  
The normal urinary proteome contains a small but discrete amount of proteins. In 
pathological situations the urinary proteome can provide information regarding damage to all 
segments of the nephron, underscoring the physiological and biological processes taking 
place. There are different proteomic approaches which present different advantages and 
disadvantages. The more traditional separation of proteins with two-dimensional gel 
electrophoresis followed by mass spectrometry (2D-electophoresis-MS) is labor intensive, 
may show poor reproducibility and requires a large amount of protein. It has a narrow 
dynamic range and cannot detect small (<10kDa), large (>150 kDa), hydrophobic or low 
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abundance proteins [96]. Liquid chromatography coupled to mass spectrometry (LC-MS) can 
be automated, is less time consuming, uses lower sample volumes and displays better 
sensitivity for smaller or hydrophobic proteins than 2DE-MS.  
 
Surface-enhanced laser desorption/ionization time of flight (SELDI-TOF) technology uses 
protein-chip arrays coupled to a TOF mass spectrometer. These chips feature different 
surface binding properties (hydrophilic or hydrophobic materials, anionic or cationic, lectin, 
or antibody affinity reagents) leading to the binding of different proteins or peptides 
depending upon their properties. SELDI-TOF is widely used as it is high throughput and an 
easy to use technique that can be automated. It uses very small sample volumes, does not 
require pre-treatment of the sample and is sensitive for detection of low molecular weight 
proteins. SELDI-TOF has been widely used in LN but has two main disadvantages. Firstly, it 
identifies patterns of protein expression rather than specific proteins, and requires subsequent 
chromatographic enrichment and protein sequencing by capillary liquid chromatography-
nanospray tandem mass spectrometry (LC/MS/MS), or on-chip protein sequencing using an 
LC/MS/MS system integrated with the SELDI-TOF mass spectrometer. The latter technique 
is limited to specific proteins, influencing the ability to undertake hypothesis free proteomic 
screening [96,97]. Secondly, intra / inter-assay coefficients of variation for protein peak 
abundance and intensities are approximately 20%, making the technique semi-quantitative, 
and requiring validation by another method [97-99]. Advancements in proteomics have 
provided considerable insight into the LN human urine proteome, and in this section, we will 
review the insights gained from paediatric and adult urine proteomic studies.  
6.1! Adult proteomic studies 
One of the earliest LN urinary proteomic studies by Mosley et al [100] used SELDI-TOF, 
identifying two proteins with masses of 3340 and 3980 which distinguished active from 
inactive LN, each with 92% sensitivity and specificity. This study featured a limited 
prospective longitudinal component including six patients, showing these proteins to predict 
both relapse and response to treatment earlier than traditional clinical markers. Using 2D-
electrophoresis in 16 patients with LN, focal segmental glomerulosclerosis (FSGS), diabetic 
and membranous nephropathy, Varghese et al [25] used patterns of protein abundance to train 
an artificial neural network to create a prediction algorithm for identification of each disease. 
In an external validation set of 16 patients, the artificial neural network was found to be best 
for LN identification with a sensitivity of 86%, specificity of 89% and AUC of 0.84. Mass 
spectrometry was used to determine the identity of the proteins which included α1-acid-
glycoprotein (AGP), transferrin (TF), zinc α-2-glycoprotein (ZA2G), α-1- microglobulin, α-
1-antitrypsin, plasma retinol binding protein (RBP), haptoglobin, complement factor B, 
transthyretin, hemopexin and albumin. The same group went on to undertake a 
complementary study using a similar approach (2D-electrophoresis followed by mass 
spectrometry, artificial neural network) to differentiate ISN/RPS LN classes using urine from 
20 patients immediately before renal biopsy. The sensitivity and specificity of the different 
combinations for the ISN/RPS classes was class II 100%, 100%; III 86%, 100%; IV 100%, 
92%; and V 92%, 50%. The 50% class V LN specificity was due to inclusion of patients with 
mixed class III, IV, V. These patients were correctly identified as having class III or IV 
disease which is more clinically appropriate. The top two proteins contributing most to the 
tests sensitivity were found to be AGP and α-1 microglobulin [101]. 
 
Zhang et al [102] subsequently sought to screen the low molecular weight proteome 
(<20kDa) in samples taken at baseline, pre-flare, flare, and post-flare by fractionating the 
urine to remove proteins larger than 30 kDa, and then spotting them onto weak cation 
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exchanger protein chips for analysis by SELDI-TOF MS. 19 patients were included with 
class III (n=5), class IV (n=11), or class V (n=3) LN. 27 protein ions were found to be 
differentially expressed between specific flare intervals. Using on-chip peptide sequencing by 
integrated tandem mass spectrometry a 20 amino acid isoform of Hepcidin and an albumin 
fragment (N-terminal region) were found to be increased 4 months pre-flare and returned to 
baseline at the time of renal flare, whereas a 25 amino acid isoform of Hepcidin decreased 
during a renal flare and returned to baseline 4 months post-flare (marker of treatment 
response). They also found α-1-antitrypsin to be increased at the time of flare.  
Somparn et al [26] undertook 2D electrophoresis on samples from 5 active and 5 in-active 
LN patients, revealing 16 protein spots whose levels differed significantly between the 
groups (serotransferrin, AGP, alpha-2-HS glycoprotein, haptoglobin, alpha-1-antitrypsin, 
albumin, ZA2G (3 isoforms), immunoglobulin kappa chain (3 forms), RBP-4, beta-2-
microglobulin, transthyretin and prostaglandin-H2-D isomerase (PGDS)). They choose to 
validate two of the markers; ZA2G (due to the magnitude of it’s change) and PGDS (because 
of its presence only in active LN), by ELISA in 30 active LN, 26 inactive LN, 14 non-LN 
glomerular diseases and 8 HC’s. Urinary ZA2G levels significantly differentiated patients 
with active and in-active LN but were also elevated in patients with non-LN glomerular 
diseases. Urinary PGDS was only significantly elevated in active LN and is therefore thought 
to represent a LN specific biomarker.  
Paediatric proteomic studies 
Only two urinary proteomic studies have been carried out to date, both by Suzuki et al 
[27,103] in North American JSLE patients. In the first, SELDI-TOF-MS was used for 
proteomic profiling in 32 JSLE patients and 11 JIA patients. They identified a urinary 
proteomic signature consisting of eight proteins which displayed significantly higher peak 
intensities in patients with LN compared with controls or SLE patients without nephritis. 
These peaks had mass-to-charge ratios of 2.76, 22, 23, 44, 56, 79, 100, and 133. There was 
no significant difference in biomarker peak intensities between distinct WHO LN classes. 
The 22, 23, 44, 79, and 100 kDa peak were strongly correlated with renal disease activity as 
defined by the SLEDAI-2k score [103].  
 
In the second study, surface-enhanced or matrix-assisted laser desorption/ionization time-of- 
flight mass spectrometry (MALDI-TOF MS) was used to identify TF, ceruloplasmin (CP), 
AGP, lipocalin-type prostaglandin-D synthetase (L-PGDS), albumin and albumin-related 
fragments as the proteins contained within the LN urinary protein signature. 
Immunonephelometry or ELISA was then used to serially assess the ability of this protein 
signature to monitor LN disease activity over time in 98 JSLE patients and 30 JIA controls. 
All proteins were significantly higher in children with SLE than JIA. Individual urinary 
biomarkers displayed fair to good ability to identify SLEDAI or BILAG defined active LN 
(AUC values between 0.68-0.81), with the AUC improving to 0.85 when all of the 
biomarkers were considered together. Urinary levels of TF, AGP and L-PGDS increased 
significantly 3 months before the clinical (SLEDAI based) diagnosis of worsening LN. 
However, significant increases in AGP and L-PGDS levels over time were also demonstrated 
in patients with stable active LN, improved LN (AGP) and inactive LN (LPGDS) [27], 
highlighting that further prospective studies are required to improve our understanding of the 
relationship of these biomarkers to disease activity over time. There is clearly overlap 
between some but not all biomarkers identified in adult and paediatric studies, highlighting 
the importance of undertaking biomarker studies in both patient groups rather than 
extrapolating between them.  
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6.2! Validation of proteomic results 
The validity of previously established proteomic biomarkers must be assessed on separate 
groups of patients to provide independent verification of the findings and evaluation of 
biomarker sensitivity, specificity and predictive capabilities. This validation may either take 
the form of an independent proteomic study or through use of other protein binding 
techniques e.g. ELISA or multiplex assays, to quantify individual of combinations of 
biomarkers in a larger group of patients. Such techniques are quicker, usually highly sensitive 
and specific for the marker of interest, and readily available within many clinical or research 
laboratories. Table 2 lists the proteins identified in LN proteomic studies that have undergone 
internal or external validation using additional methods for protein quantification ± further 
proteomic techniques. Figure 1 also provides an overview of the evidence relating to protein 
urine biomarkers to date, and how they relate to the different clinical scenarios faced during 
the natural course of LN progression.  
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Protein Original 
proteomic 
study  
Validation Studies 
Proteomic Other methods / techniques 
Biomarkers identified in ≥2  proteomic studies and validated using other methods 
 AGP Oates 
[101] 
Varghese 
[25] 
 
Suzuki [103] 
 
Suzuki [27], 98 JSLE, ELISA’s, serially assessed AGP, TF, CP, LPGDS. AUC of 0.85 for active LN 
identification when all biomarkers combined. 
Brunner [69], 76 SLE patients, ELISA’s. AGP+MCP1+CP+protein:creatinine ratio = good for detecting 
LN histological activity (AUC 0.85). AGP+MCP-1+TF+CrCl+C4 = fair for membranous LN detection 
(AUC 0.75). 
Watson [42], 60 JSLE patients, ELISA. Urinary AGP significantly elevated in active LN. 
TF Varghese 
[25] 
Suzuki [103] Suzuki [27] – as described above 
Brunner [69] – as described above 
ZA2G Varghese 
[25]  
Somparn 
[26] 
Somparn [26], ELISA, 30 active LN, 26 inactive, 14 non-LN kidney disease. ZA2G levels higher in 
active LN. 
RBP-4 Varghese 
[25] 
Somparn 
[26] 
Sesso [104], 70 SLE patients, immunoenzymometric assay. RBP-4 significantly higher in active LN. 
Marks [105], 21 JSLE patients, 10 active LN, 11 inactive, ELISA. RBP levels significantly higher in 
active LN.   
PGDS or 
LPGDS 
Suzuki 
[103]  
 
 
Somparn 
[26] 
Suzuki [27] – as described above 
Somparn [26], ELISA, 30 active LN, 26 inactive LN, 14 non-LN kidney disease, 8 HC’s, PDGS 
significantly elevated in active LN. 
Gupta [106] 28 SLE patients with active LN, 6 inactive SLE, 12 active non-renal disease and 19 HC’s. 
ELISA. Significantly higher levels in active-LN. Levels fell in those responding to LN treatment and 
remained elevated in patients developed chronic kidney disease.  
Biomarkers identified in a single proteomic study and validated using another technique 
Hemopexin Varghese 
[25] 
NA Brunner [95], 47 active LN JSLE patients, ELISA. National Institute for Health Activity Index status 
predicted by NGAL, MCP-1, CP, adiponectin and KIM-1, Hemopexin in combination. 
Hepcidin  Zhang 
[102] 
NA Mohammed [107], 30 active LN, 30 non-LN SLE patients and 30 HC’s, ELISA. Hepcidin higher in 
active LN.  
Κ-FLC  Somparn 
[26]  
NA Hanaoka [38], 43 SLE patients, Nephrometric assay. Both κ/λ FLC’s increased in class III/IV LN vs 
I/II/IV. 
β2MG Somparn 
[26] 
NA Tsai [89], 15 active LN, 12 with in-active LN, ELISA. Levels did not differ between groups. 
Choe [108], 64 SLE patients, ELISA, significantly higher in patients with active LN. 
CP  Suzuki 
[103]  
NA Suzuki [27] - as described above 
Brunner  [69] - as described above, Brunner [95] - as described above 
Angiostatin Wu [109] NA Wu [109], 100 SLE, 24 CKD patients and 30 HC’s. ELISA, angiostatin identified active AUC = 0.83 
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Table 2: Proteins identified in LN proteomic studies that have undergone validation 
using additional methods for protein quantification ± further proteomic techniques. 
Abbreviations = AGP = α-1 acid glycoprotein. TF = transferrin. CP = ceruloplasmin, MCP-1 
= monocyte chemoattractant protein. CrCl = Creatinine Clearance. ZA2G = Zinc α-2-
glycoprotein. HC’s = healthy controls. RBP= plasma retinol binding protein. PGDS = 
Prostaglandin-H2-D isomerase, alternative name LPGDS = Lipocalin- type prostaglandin-D 
synthetase. Hepcidin = 20 & 25 amino acid isoforms. Κ-FLC= κ free light chain. β2MG = 
Beta-2-microglobulin. CKD = chronic kidney disease patients. 
7! Origin / role of key proteins identified and validated in paediatric proteomic studies 
It is interesting to consider the role and origin of proteins which have been identified in 
proteomic studies and validated extensively. AGP (also called Orosomucoid) belongs to the 
immunocalin family, a group of binding proteins which binds and transport small 
hydrophobic molecules and also has immunomodulatory functions. AGP is also one of the 
major acute phase proteins, which is mainly secreted by hepatocytes as part of the systemic 
response to inflammatory mediators (IL-1, IL-6, IL-8) or stressful stimuli such as physical 
trauma or bacterial infections. AGP production has also been reported in several tissues 
outside the liver including alveolar stimulated macrophages [110], human endothelial cells 
[111], cultured monocytes [112,113], resting and activated polymorphs [114,115]. L-PGDS is 
secretory protein of the lipocalin superfamily that acts as an enzyme responsible for the 
production of prostaglandin D2. It is produced in the brain by the choroid plexus or 
leptomeninges and is continuously secreted through cerebrospinal fluid into blood. L-PGDS 
is similar to albumin in chemical properties but is much smaller, allowing it to pass more 
readily through the glomerular capillary walls [116]. 
 
CP is involved in the metabolism of iron and carries the vast amount of circulating copper in 
the plasma [117]. TF is a metal binding protein with high affinity for iron, binding and 
moving it into cells and tissues. Iron is important to normal immune function, contributing to 
cell differentiation and growth. Alterations in iron homeostasis have been associated with 
several rheumatological and autoimmune disease [118]. Both CP and TF differ from albumin 
in terms of their molecular radii and isoelectric points, and have been shown to predict the 
onset of microalbuminuria at an earlier stage in conditions such as type 2 diabetes [119,120]. 
RBP-4 is mainly secreted by hepatocytes and adipose tissue, and also belongs to the lipocalin 
family. It is a carrier for retinol (vitamin A), delivering it to peripheral tissues, and urinary 
RBP-4 has been shown to be a biomarker for proximal renal tubule dysfunction [121]. 
Hemopexin is an acute phase reactant which is synthesized in the liver, binding and 
neutralizes pro-oxidant free heme, protecting the body from oxidative damage and preserving 
iron stores [122]. 
 
8! Metabolites 
Metabolomics is a systems biology approach which investigates the overall metabolic activity 
of an individual, taking into account the influence of the genetic background and 
environment. Just as transcriptomics involves the study of gene expression, and proteomics 
the expression of proteins, metabolomics investigates the consequences of the activity of 
these genes and proteins, providing information on an individuals small molecule metabolite 
profile and unique chemical fingerprint [123]. To date there has been one small study looking 
at urinary metabolites in LN. This study included seven patients with class III/IV LN and 
seven with class V LN, utilising NMR spectroscopy based metabolic profiling. Significant 
differences were identified in citrate and taurine levels between class III/IV and V LN 
patients [124]. Currently there is no consensus on the best approach for normalisation of 
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metabolomics results from urine samples taking urinary dilution into account [125]. Further 
work is required extending these interesting analyses to larger patient cohorts, applying a 
normalisation factor and validating results using alternative techniques.  
 
9! Conclusions - the future of urine biomarkers in LN 
There have been an increasing number of promising urine biomarker studies over the last 10-
15 years which have investigated a variety of biomarkers for LN. Early research into 
biomarker identification is becoming simpler through novel cutting edge technologies, which 
measure individual or combinations of biomarkers in miniscule patient samples.  These data 
have provided insights into the pathophysiology and monitoring of LN but have not been 
translated into clinical practice, with the majority of studies concluding after the first or 
second phases of biomarker discovery. Moving such discoveries forward towards translation 
is complex and reliant upon studies which are carefully planned to avoid common pitfalls 
relating to sample size, accuracy of patient stratification over time, variation in the standard 
operating procedures for sample selection, collection, storage, handling, analysis and data 
interpretation. LN urine biomarker studies vary in terms of the outcome measures used to 
define active LN, with some studies relying upon composite disease activity measures (e.g. 
renal BILAG or SLEDAI) and others upon histological classification of LN (e.g. ISN/RPS 
classification, WHO criteria, National Institute for Health (NIH) activity, chronicity or 
tubular indices). Kidney biopsy is considered the gold standard test for LN, but unfortunately 
is also imperfect, relying on an invasive procedure for sampling and the subjective 
appearance of a few glomeruli in what can be a patchy disease. 
 
The above methodological aspects and difficulties in LN urine biomarkers studies have 
impacted upon the perceived sensitivity, specificity, and predictive value of biomarkers thus 
far. Going forwards, it is important that the promising markers identified so far are further 
nurtured and internationally validated in adequately powered paediatric and adult SLE 
collaborative longitudinal studies, allowing us to move these discoveries towards clinical 
translation. Opportunities to include both paediatric and adult patients in urine biomarker 
studies should not be missed but considered integral to the development process, as is 
increasingly becoming the case in drug development. For such a study to be possible, the 
international community must assess and agree the measures which should be used to assess 
for active LN, with consideration as to whether more comprehensive validation is required of 
the disease activity measures for identification of active LN.  
 
We must move from designing studies which do not only stratify patients as active / in-active 
LN but answer clinically important questions relating to the ability of biomarkers to predict a 
LN flare, identify active LN / evaluate its severity, determine response to a variety of 
treatments and assess for the presence of chronic renal damage over time. It has increasingly 
become clear that an individual biomarker will not provide optimal specificity and sensitivity 
in isolation, and that use of a combinatorial approach is of immense importance. Figure 2 
shows a representation of the forecasted exciting future utility of urine biomarkers in LN 
monitoring and management. Our objective should therefore be the implementation of 
international collaborative efforts within paediatric and adult rheumatology communities for 
translating experimental findings into clinical trials, to make these ideals a reality. 
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Figure Legends 
 
Figure 1: Overview of the evidence relating to urine biomarkers to date and how they 
relate to distinct clinical questions in LN monitoring. Markers which are A) early 
predictors of flare, B) able to identify an active LN flare, C) used to evaluate flare severity, 
D) for identification of treatment non-responders, E) to identify chronic kidney damage. 
Urinary biomarkers shown in black are from paediatric studies, those in grey are from adult 
studies. NGAL = neutrophil gelatinase associated lipocalin. AGP = α-1 acid glycoprotein. TF 
= transferrin. CP = ceruloplasmin. LPGDS = Lipocalin- type prostaglandin-D synthetase. 
MCP1 = monocyte chemoattractant protein. VCAM-1 = vascular cell adhesion molecule 1. 
TWEAK = tumor necrosis like weak inducer of apoptosis. RBP= plasma retinol binding 
protein. Il-6 = interleukin 6. CXCL16 = Chemokine (C-X-C motif) ligand 16. RANTES = 
Regulated on Activation, Normal T Expressed and Secreted, ZA2G = Zinc α-2-glycoprotein. 
ISN/RPS = International Society of Nephrology / Renal Pathology Society classification. 
CrCl = Creatinine Clearance. Κ/L-FLC= κappa / lamda free light chains. IP-10 = Interferon 
gamma-induced protein 10. CXCR3 = Chemokine (C-X-C Motif) Receptor 3. NIH = national 
institute for health. UPUC = urine protein/creatinine ratio. KIM-1 = kidney injury molecule 
1. 
 
Figure 2: Future utility of urine biomarkers in LN monitoring and management. NGAL 
= neutrophil gelatinase associated lipocalin. AGP = α-1 acid glycoprotein. TF = transferrin. 
CP = ceruloplasmin. LPGDS = Lipocalin- type prostaglandin-D synthetase. VCAM-1 = 
vascular cell adhesion molecule 1. TWEAK = tumor necrosis like weak inducer of apoptosis. 
RBP= plasma retinol binding protein. Il-6 = interleukin 6. CXCL16 = Chemokine (C-X-C 
motif) ligand 16. RANTES = Regulated on Activation, Normal T Expressed and Secreted, 
ZA2G = Zinc α-2-glycoprotein. ISN/RPS = International Society of Nephrology / Renal 
Pathology Society classification. Κ/L-FLC= κappa / lamda free light chains. MCP1 = 
monocyte chemoattractant protein. IP-10 = Interferon gamma-induced protein 10. CXCR3 = 
Chemokine (C-X-C Motif) Receptor 3. CrCl = Creatinine Clearance. C4 = complement factor 
4. NIH = national institute for health. UPUC = urine protein/creatinine ratio.KIM-1 = kidney 
injury molecule 1. 
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